PMID- 30899290
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 1734-1922 (Print)
IS  - 1896-9151 (Electronic)
IS  - 1734-1922 (Linking)
VI  - 15
IP  - 2
DP  - 2019 Mar
TI  - Circulating microRNAs as biomarkers for myocardial fibrosis in patients with left 
      ventricular non-compaction cardiomyopathy.
PG  - 376-384
LID - 10.5114/aoms.2019.82919 [doi]
AB  - INTRODUCTION: Despite the fact that cardiovascular magnetic resonance (CMR) with 
      late gadolinium enhancement (LGE) is a proven method for detecting myocardial 
      fibrosis, there is a need for new and reliable serological biomarkers. 
      Circulating miRNAs could be a practical and attractive alternative. The purpose 
      of the study was to assess the miRNAs well established in myocardial fibrosis - 
      miR-21, miR-29a, miR-30d and miR-133a - in the plasma of patients with left 
      ventricular non-compaction (LVNC) that have areas of LGE assessed by CMR. 
      MATERIAL AND METHODS: We prospectively enrolled 13 adult patients (9 males and 4 
      females; mean age: 39 +/-11.7 years) considered to meet standard CMR criteria for 
      LVNC and 10 healthy age- and sex-matched subjects. All LVNC patients and control 
      subjects underwent CMR examination and the measurement of peripheral plasma 
      levels of 4 miRNAs: miR-21, miR-29a, miR-30d and miR-133a. RESULTS: The LGE was 
      present in 9 of the 13 (69.2%) LVNC patients, and most often located in the 
      ventricular septum. Compared with LGE-negative patients, LGE-positive patients 
      had significantly lower LVEF (28.3 +/-13.3% vs. 53.5 +/-14.9%, p = 0.0113) and 
      greater LV end-diastolic diameter (67.8 +/-9.5 mm vs. 57 +/-2.2 mm, p = 0.01). 
      Significant up-regulation of all 4 miRNAs was observed among LGE-positive 
      patients vs. LGE-negative patients: miR-21 (p = 0.007), miR-29a (p = 0.0001), 
      miR-30d (p = 0.001) and miR-133a (p = 0.0003). CONCLUSIONS: The up-regulation of 
      miR-21, miR-29a, miR-30d and miR-133a indicates the presence of LGE in LVNC 
      patients, and therefore they may serve as potential biomarkers for myocardial 
      fibrosis.
FAU - Szemraj-Rogucka, Zofia M
AU  - Szemraj-Rogucka ZM
AD  - Department of Radiology and Diagnostic Imaging, Medical University of Lodz, 
      Central Clinical Hospital, Lodz, Poland.
FAU - Szemraj, Janusz
AU  - Szemraj J
AD  - Department of Medical Biochemistry, Medical University of Lodz, Lodz, Poland.
FAU - Masiarek, Konrad
AU  - Masiarek K
AD  - Department of Interventional Cardiology and Cardiac Arrhythmias, Medical 
      University of Lodz, Medical University Teaching Hospital, Lodz, Poland.
FAU - Majos, Agata
AU  - Majos A
AD  - Department of Radiology and Diagnostic Imaging, Medical University of Lodz, 
      Central Clinical Hospital, Lodz, Poland.
LA  - eng
PT  - Journal Article
DEP - 20190304
PL  - Poland
TA  - Arch Med Sci
JT  - Archives of medical science : AMS
JID - 101258257
PMC - PMC6425222
OTO - NOTNLM
OT  - cardiac magnetic resonance
OT  - late gadolinium enhancement
OT  - left ventricular non-compaction
OT  - miRNA
COIS- The authors declare no conflict of interest.
EDAT- 2019/03/23 06:00
MHDA- 2019/03/23 06:01
PMCR- 2019/03/01
CRDT- 2019/03/23 06:00
PHST- 2017/01/14 00:00 [received]
PHST- 2017/03/22 00:00 [accepted]
PHST- 2019/03/23 06:00 [entrez]
PHST- 2019/03/23 06:00 [pubmed]
PHST- 2019/03/23 06:01 [medline]
PHST- 2019/03/01 00:00 [pmc-release]
AID - 35833 [pii]
AID - 10.5114/aoms.2019.82919 [doi]
PST - ppublish
SO  - Arch Med Sci. 2019 Mar;15(2):376-384. doi: 10.5114/aoms.2019.82919. Epub 2019 Mar 
      4.